Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 2Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 6Breast 3Genitourinary 2Tumor-Agnostic 1Head & Neck 1Gynecologic 1CNS 1

Conditions

Thyroid Nodule 1

Interventions

Cisplatin 263Radiotherapy 166Cetuximab 159Docetaxel 105Fluorouracil 104pembrolizumab 94Radiotherapy, Intensity-Modulated 83Carboplatin 80Paclitaxel 73Nivolumab 59Erlotinib Hydrochloride 35Surveys and Questionnaires 32Gemcitabine 32durvalumab 30Radiation 29Drug Therapy 25Immunohistochemistry 21Gefitinib 21Capecitabine 21tremelimumab 18Bevacizumab 18Surgical Procedures, Operative 17Sorafenib 17Magnetic Resonance Spectroscopy 17Ipilimumab 17Pemetrexed 16lenvatinib 15atezolizumab 15Radiosurgery 15Gene Expression Profiling 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Drug Delivery Systems × Head & Neck × Clear all
NCT06117085 2024-11-21

CellFX ® Percutaneous Electrode (PE) Treatment of Symptomatic Benign Thyroid Nodules

Pulse Biosciences, Inc.

Phase NA Completed
30 enrolled
Head & Neck

Thyroid Nodule

Data powered by HemOnc (CC BY 4.0) Colophon âš¡